Company news
Arrowhead Pharmaceuticals, Inc. news in 2020
Arrowhead Pharmaceuticals, Inc.'s news releases, calls and decks from 2020, newest first.
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
December 6, 2020
NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer
December 1, 2020
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda
November 24, 2020
Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results
November 22, 2020
Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020
November 12, 2020
Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease
November 12, 2020
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
November 3, 2020
Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results
November 1, 2020
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
October 7, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference
September 29, 2020
Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment
September 15, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences
September 7, 2020
Arrowhead Pharmaceuticals Appoints Oye Olukotun to Board of Directors
September 7, 2020
Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020
August 30, 2020
Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress
August 27, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences
August 17, 2020
Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
August 17, 2020
Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis
August 10, 2020
Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results
August 4, 2020
Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890
July 28, 2020
Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
July 27, 2020
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
July 8, 2020
Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Third Quarter Results
July 7, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming June 2020 Conferences
May 27, 2020
Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results
May 6, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences
April 30, 2020
Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given
April 30, 2020
Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Second Quarter Results
April 21, 2020
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis
April 9, 2020
Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread
March 16, 2020
Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH
March 2, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming March 2020 Conferences
March 1, 2020
Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
February 4, 2020
Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results
February 4, 2020
Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results
January 21, 2020
Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer
January 5, 2020